CJC-1295 vs Sermorelin vs Ipamorelin

CJC-1295, Sermorelin, and Ipamorelin get grouped together a lot. The research literature treats all three as compounds that interact with growth hormone (GH) secretion pathways. They are sold for research use and are not approved for human consumption. But they work through different mechanisms, and their pharmacokinetic profiles are far apart. Researchers account for that when designing study protocols.

Mechanisms: Two Different Pathways

Sermorelin and CJC-1295 are both GHRH analogs: synthetic peptides that mimic growth hormone-releasing hormone (GHRH), the endogenous signal released by the hypothalamus. They bind to the GHRH receptor (GHRHR) on pituitary somatotroph cells, which stimulates pulsatile release of GH. Sermorelin is a truncated analog containing the first 29 amino acids of endogenous GHRH (GRF 1-29). CJC-1295 is a modified version engineered for a much longer half-life through a technology that promotes albumin binding, often referred to in research as Drug Affinity Complex (DAC) technology. Published descriptions attribute the extension to a maleimidopropionyl group that bonds to circulating albumin, shielding the peptide from rapid degradation.

Ipamorelin works on a separate receptor class entirely. It is a ghrelin receptor agonist (also called a growth hormone secretagogue receptor, or GHSR, agonist). Instead of mimicking GHRH, it mimics ghrelin's action at the GHSR-1a receptor and triggers GH release through a different signaling pathway. Raun and colleagues first characterized it in a 1998 paper in the European Journal of Endocrinology as "the first selective growth hormone secretagogue," a pentapeptide reported to stimulate GH without significantly raising ACTH, cortisol, or prolactin, even at doses well above the dose that produces half-maximal GH release.

Half-Life and Selectivity Differences

Half-life is the distinction researchers cite most. Sermorelin has a short half-life, commonly described in pharmacological literature as roughly 10–12 minutes in circulation, which reflects rapid enzymatic degradation. That means research protocols need pulsatile dosing to observe sustained GH output. CJC-1295, because of its albumin-binding DAC modification, is reported in research to last much longer. Descriptions place it on the order of days rather than minutes, with single-dose studies reporting elevated GH and IGF-1 markers persisting for several days, which allows less frequent administration windows in research contexts. Ipamorelin sits between the two: longer than Sermorelin, shorter than CJC-1295 with DAC.

Selectivity is the other axis researchers use to tell these compounds apart. Sermorelin and CJC-1295 act at the GHRHR and do not engage the ghrelin receptor pathway at all, so their selectivity question is mainly about pituitary specificity. The literature discusses Ipamorelin's selectivity differently. Researchers point to its relatively clean GH-release signal as a distinguishing feature versus older GHSR agonists, though the underlying mechanisms remain an active area of study.

Comparison at a Glance

What Research Reports — and What It Does Not

The literature on these three compounds is mostly preclinical and early-phase. Research reports differences in binding kinetics, receptor selectivity, and plasma half-life. What it does not establish, at this stage, is equivalence of outcomes in human populations, optimal dosing windows, or comparative safety profiles in long-term use. Researchers studying GH secretagogues usually pick between these compounds based on the half-life and receptor pathway that fit their experimental design. They are not picking by efficacy rankings, which rigorous comparative trials have not settled.

Regulatory Status

Of the three, only Sermorelin has ever held a U.S. marketing approval as a finished drug. Sermorelin acetate was approved decades ago under the brand name Geref, first as a pituitary-function diagnostic and later for pediatric growth hormone deficiency. A determination published in the Federal Register on March 4, 2013 records that Geref was withdrawn from sale. The FDA determined it was not withdrawn for reasons of safety or effectiveness; the withdrawal followed the manufacturer's voluntary discontinuation. No Geref-equivalent finished product is currently FDA-approved, and CJC-1295 and Ipamorelin have never been approved finished drugs.

These peptides have also figured in recent U.S. compounding-policy activity. The FDA placed several peptide bulk substances into Category 2 of its interim 503A bulks list, the category for substances with potential significant safety risks for compounding. In September 2024, it announced the removal of five substances from that category, including CJC-1295 and ipamorelin acetate, after the underlying nominations were withdrawn. The agency's Pharmacy Compounding Advisory Committee (PCAC) took up these and related peptides at meetings in late 2024. The removal reflected a procedural change in the nomination process, not an FDA finding that the substances are safe or approved for human use. Treat the compounding-regulation landscape as fluid and check the FDA's current 503A bulks list for status.

Anyone encountering these peptides outside a licensed research context should know they are not approved pharmaceutical products in major regulatory jurisdictions. The characterizations above reflect what the research literature and regulatory record describe, not clinical guidance.

Sources

• Raun K. et al., "Ipamorelin, the first selective growth hormone secretagogue," Eur J Endocrinol (1998) — PubMed
• Ishida J. et al., "Growth hormone secretagogues: history, mechanism of action, and clinical development," JCSM Rapid Communications (2020)
• FDA — Determination that GEREF (Sermorelin Acetate) Injection Was Not Withdrawn for Reasons of Safety or Effectiveness (Federal Register, 2013)
• FDA — Pharmacy Compounding Advisory Committee (PCAC) briefing materials
• Modified GRF (1-29) — overview reference)
• Finnrick — peptide research aggregator
• Peptigrity — peptide information resource